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Nicotine patches with 
e-cigarettes for smoking 
cessation: Twitter 
discussion from a 
respirology journal club
Authors’ reply
The Lancet Respiratory Medicine 
published a letter by Nermin Diab and 
colleagues (2020)1 about our three-arm 
trial investigating the effectiveness and 
safety of nicotine patches combined 
with e-cigarettes (with and without 
nicotine) for smoking cessation.2 We 
wish to address two points made by 
the authors of the letter.
First, they say, “…it would seem 
preferable to establish the efficacy of 
nicotine e-cigarettes before doing a 
pragmatic trial”. 1 We would suggest that 
both efficacy and effectiveness trials are 
important, but they serve very different 
purposes and provide very different 
information. Both designs have pros 
and cons—the choice of design relates 
to the research question of interest, is 
context specific, and one does not need 
to occur before the other. Efficacy trials 
are highly controlled (both in patient 
population and conduct) and their 
findings are therefore not translatable 
to the real world. In comparison, trials 
on the effectiveness of e-cigarettes 
have the most relevance for decision 
making by health-care policy makers 
and health-care providers. Such trials 
tend to have a usual care comparator, 
but can be expensive to do as they 
often require a large sample size and 
long-term follow-up. It is important 
when reading effectiveness trials to 
consider the context of the trial (ie, 
the country in which it was done, and 
the country’s policy environment). In 
New Zealand, a country with a smoke-
free 2025 goal and the urgent need for 
policy relevant information about the 
effect of e-cigarettes on quitting, our 
effectiveness trial design was the most 
appropriate design to answer the policy-
based research question.
When our trial findings are 
considered in their entirety, one can see 
that they are consistent across different 
time points, measures of cessation, 
and with most of the sensitivity 
analyses supporting the conclusions. 
We acknowledge the authors’ 
comments about the desirability for 
more frequent verification of smoking 
status. However, New Zealand is a small 
country (of approximately 5 million 
people) with little public research 
funding available. It was not feasible or 
affordable to do more extensive follow-
up of our trial participants, as they were 
geographically dispersed throughout 
the entire country and we had only 
around US$400 000 to run a three-
year trial. Our chosen measurements 
of abstinence are those recommended 
by the Society for Research on Nicotine 
and Tobacco for pragmatic trials.3 In 
New Zealand, we do not have access 
to large pools of research funding, so 
must maximise our use of every dollar. 
Efficacy trials of little relevance to the 
population using e-cigarettes are a 
poor use of our time and money.
Second, they say, “…the findings are 
not readily generalisable given the 
multitude of e-cigarette brands and 
delivery systems available worldwide 
and probably different amounts of 
nicotine content from that used in 
the trial.” 1 We agree, but no efficacy 
or effectiveness trial of e-cigarettes 
will ever be fully generalisable. Nor 
is it possible to design a trial where 
every type of e-cigarette ever designed 
(and nicotine concentration) can be 
evaluated. However, there are other 
pathways to inference than those of 
drug evaluation. In this case we have 
created generalisable evidence as proof 
of principle that nicotine-containing 
e-cigarettes combined with nicotine 
patches will increase quit rates. We 
tested the type of e-cigarette (and 
nicotine concentration) that was 
the most popular amongst naive 
e-cigarette users in New Zealand at the 
time the trial was done. Newer devices 
are known to deliver nicotine more 
efficiently and effectively, so one can 
assume quit rates would be higher.
NW, CB, MV, GL, ML, and VP report grants from the 
Health Research Council of New Zealand, during the 
conduct of the study. NW, CB, MV, and VP report 
grants from Pfizer, outside of the submitted work. 
GL chairs the organisation End Smoking New 
Zealand, which advocates for harm reduction 
approaches to tobacco control. E-cigarettes were 
purchased from a New Zealand e-cigarette online 
retailer (NZVAPOR, https://www.nzvapor.com/), 
e-liquid was purchased from Nicopharm, Australia 
(https://www.nicopharm.com.au/), and nicotine 
patches were supplied by the New Zealand 
Government via their contract with Novartis 
(Sydney, Australia). NZVAPOR also provided, at no 
cost to participants, online and phone support 
regarding use of the e-cigarettes. Neither NZVAPOR 
nor Nicopharm have links with the tobacco industry. 
None of the above parties had any role in the 
design, conduct, analysis, or interpretation of the 
trial findings, or writing of this publication.
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